M7824

Methotrexate

Name: Methotrexate
Brand: SIGMA

Synonym(s):

Methotrexate, (+)-Amethopterin, 4-Amino-10-methylfolic acid, 4-Amino-N¹⁰-methylpteroyl-L-glutamic acid, Antifolan, MTX, Methylaminopterin

Select a Size

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₂₀H₂₂N₈O₅

CAS Number:

59-05-2

Molecular Weight:

454.44

EC Number:

200-413-8

UNSPSC Code:

41116107

NACRES:

NA.21

Beilstein/REAXYS Number:

70669

MDL number:

MFCD00064370

InChI

1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1

InChI key

FBOZXECLQNJBKD-ZDUSSCGKSA-N

SMILES string

CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O

biological source

synthetic

form

powder

suitability

suitable for manufacturing use

storage temp.

−20°C

Quality Level

400

Gene Information

human ... DHFR(1719)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Bioprocessing & Formulation Raw Materials

Pharma & Biopharma Manufacturing

Upstream Process Chemicals

General description

Inhibits thymidylate synthetase, is a nonselective de novo purine synthesis inhibitor and has a significant toxicity profile including hepatotoxicity, pneumonitis and bone marrow suppression. Potent folic acid antagonist. Induces apoptosis in HL-60 human leukemia cells. Also useful as an anti-tumor agent.

Our SAFC^® portfolio of high-quality raw materials for use in biopharmaceutical processing withstands strict quality control procedures plus the documentation and expertise to help our customers meet requirements as defined by the M-Clarity Program.

M-Clarity Program

Our comprehensive portfolio of upstream process chemicals not only provides biopharmaceutical manufacturers with high-quality raw materials for production of classical and novel therapies, but also helps them get to market faster and simplify regulatory challenges. Trust us to deliver supply chain transparency and reliable sourcing around the globe, streamlining your product qualification with best-in-class regulatory support and service.

Legal Information

SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

GHS06,GHS08

signalword

Danger

hcodes

H301,H341,H360D,H372

pcodes

P202 - P260 - P264 - P280 - P301 + P310 - P405

Hazard Classifications

Acute Tox. 3 Oral - Muta. 2 - Repr. 1B - STOT RE 1

target_organs

Liver,Bone marrow

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

0000507508

0000491173

0000502828

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Deep sequencing reveals different compositions of mRNA transcribed from the F8 gene in a panel of FVIII-producing CHO cell lines.

Christian S Kaas et al.

Biotechnology journal, 10(7), 1081-1089 (2015-05-13)

Coagulation factor VIII (FVIII) is one of the most complex biopharmaceuticals due to the large size, poor protein stability and extensive post-translational modifications. As a consequence, efficient production of FVIII in mammalian cells poses a major challenge, with typical yields

Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial.

Axel Finckh et al.

Arthritis research & therapy, 16(5), 458-458 (2014-10-16)

Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX) in chronic or recurrent CPPD arthropathy. Patients with CPPD arthropathy

Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010.

Anna-Birgitte Aga et al.

Annals of the rheumatic diseases, 74(2), 381-388 (2013-11-29)

To investigate whether baseline disease activity levels and responses in patients with rheumatoid arthritis (RA) changed during the period 2000-2010. Data were provided by the Norwegian disease-modifying antirheumatic drug (NOR-DMARD) study. Patients with inflammatory joint diseases starting new treatment with

Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial.

Joshua F Baker et al.

Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)

To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th

Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.

Giovanni L Mancardi et al.

Neurology, 84(10), 981-988 (2015-02-13)

To assess in multiple sclerosis (MS) the effect of intense immunosuppression followed by autologous hematopoietic stem cells transplantation (AHSCT) vs mitoxantrone (MTX) on disease activity measured by MRI. We conducted a multicenter, phase II, randomized trial including patients with secondary

View All Related Papers